Literature DB >> 22486311

Protective B-cell epitopes of Francisella tularensis O-polysaccharide in a mouse model of respiratory tularaemia.

Zhaohua Lu1, Guillermo Madico, Marly I Roche, Qi Wang, Julia H Hui, Hillary M Perkins, Joseph Zaia, Catherine E Costello, Jacqueline Sharon.   

Abstract

Antibodies to the lipopolysaccharide (LPS) of Francisella tularensis have been shown to be protective against respiratory tularaemia in mouse models, and we have previously described mouse monoclonal antibodies (mAbs) to non-overlapping terminal and internal epitopes of the F. tularensis LPS O-polysaccharide (OAg). In the current study, we used F. tularensis LPS oligosaccharides of defined OAg repeat length as molecular rulers in competition ELISA to demonstrate that the epitope targeted by the terminal OAg-binding mAb FB11 is contained within one tetrasaccharide repeat whereas the epitope targeted by the internal OAg-binding mAb Ab52 spans two tetrasaccharide repeats. Both mAbs conferred survival to BALB/c mice infected intranasally with the F. tularensis type B live vaccine strain and prolonged survival of BALB/c mice infected intranasally with the highly virulent F. tularensis type A strain SchuS4. The protective effects correlated with reduced bacterial burden in mAb-treated infected mice. These results indicate that an oligosaccharide with two OAg tetrasaccharide repeats covers both terminal and internal protective OAg epitopes, which may inform the design of vaccines for tularaemia. Furthermore, the FB11 and Ab52 mAbs could serve as reporters to monitor the response of vaccine recipients to protective B-cell epitopes of F. tularensis OAg.
© 2012 The Authors. Immunology © 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22486311      PMCID: PMC3385035          DOI: 10.1111/j.1365-2567.2012.03589.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  53 in total

1.  Model-building study of the combining sites of two antibodies to alpha (1----6)dextran.

Authors:  E A Padlan; E A Kabat
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

2.  In vivo and in vitro labelling of epithelial tumor cells with anti 17-1A monoclonal antibodies in bone marrow of cancer patients.

Authors:  G Schlimok; H Göttlinger; I Funke; S Swierkot; H Häuser; G Riethmüller
Journal:  Hybridoma       Date:  1986-07

3.  Immunochemical characterization of binding sites of hybridoma antibodies specific for alpha (1 leads to 6) linked dextran.

Authors:  J Sharon; E A Kabat; S L Morrison
Journal:  Mol Immunol       Date:  1982-03       Impact factor: 4.407

4.  The subsites of monoclonal anti-dextran IgA W3129.

Authors:  C P Glaudemans; P Kovác; A S Rao
Journal:  Carbohydr Res       Date:  1989-07-15       Impact factor: 2.104

5.  Genetic modification of the O-polysaccharide of Francisella tularensis results in an avirulent live attenuated vaccine.

Authors:  Tae-Hyun Kim; Jessica T Pinkham; Sara J Heninger; Sabina Chalabaev; Dennis L Kasper
Journal:  J Infect Dis       Date:  2011-10-03       Impact factor: 5.226

6.  A synthetic heptasaccharide reveals the capability of a monoclonal antibody to read internal epitopes of a polysaccharide antigen.

Authors:  T Ziegler; P Kovác; C P Glaudemans
Journal:  Carbohydr Res       Date:  1990-08-15       Impact factor: 2.104

7.  Binding characteristics of IgA 16.4.12E, a monoclonal antibody with specificity for the nonreducing terminal epitope of alpha-(1----6)-dextrans. Comparisons between IgA hybridoma 16.4.12E and myeloma W3129.

Authors:  E M Nashed; G R Perdomo; E A Padlan; P Kovác; T Matsuda; E A Kabat; C P Glaudemans
Journal:  J Biol Chem       Date:  1990-11-25       Impact factor: 5.157

8.  Characterization of the O antigen gene cluster and structural analysis of the O antigen of Francisella tularensis subsp. tularensis.

Authors:  Joann L Prior; Richard G Prior; Paul G Hitchen; Helen Diaper; Kate F Griffin; Howard R Morris; Anne Dell; Richard W Titball
Journal:  J Med Microbiol       Date:  2003-10       Impact factor: 2.472

9.  Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody.

Authors:  D M Herlyn; Z Steplewski; M F Herlyn; H Koprowski
Journal:  Cancer Res       Date:  1980-03       Impact factor: 12.701

10.  Characterization of five Shigella flexneri variant Y-specific monoclonal antibodies using defined saccharides and glycoconjugate antigens.

Authors:  N I Carlin; D R Bundle; A A Lindberg
Journal:  J Immunol       Date:  1987-06-15       Impact factor: 5.422

View more
  12 in total

Review 1.  Discovery of protective B-cell epitopes for development of antimicrobial vaccines and antibody therapeutics.

Authors:  Jacqueline Sharon; Michael J Rynkiewicz; Zhaohua Lu; Chiou-Ying Yang
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

2.  Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies.

Authors:  Linxiao Chen; Jenny L Valentine; Chung-Jr Huang; Christine E Endicott; Tyler D Moeller; Jed A Rasmussen; Joshua R Fletcher; Joseph M Boll; Joseph A Rosenthal; Justyna Dobruchowska; Zhirui Wang; Christian Heiss; Parastoo Azadi; David Putnam; M Stephen Trent; Bradley D Jones; Matthew P DeLisa
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-06       Impact factor: 11.205

3.  Structural analysis of a protective epitope of the Francisella tularensis O-polysaccharide.

Authors:  Michael J Rynkiewicz; Zhaohua Lu; Julia H Hui; Jacqueline Sharon; Barbara A Seaton
Journal:  Biochemistry       Date:  2012-07-02       Impact factor: 3.162

4.  Antibodies to both terminal and internal B-cell epitopes of Francisella tularensis O-polysaccharide produced by patients with tularemia.

Authors:  Zhaohua Lu; Hillary M Perkins; Jacqueline Sharon
Journal:  Clin Vaccine Immunol       Date:  2013-12-18

5.  B1a cells enhance susceptibility to infection with virulent Francisella tularensis via modulation of NK/NKT cell responses.

Authors:  Deborah D Crane; Amanda J Griffin; Tara D Wehrly; Catharine M Bosio
Journal:  J Immunol       Date:  2013-02-01       Impact factor: 5.422

6.  Functional and structural characterization of Francisella tularensis O-antigen antibodies at the low end of antigen reactivity.

Authors:  Zhaohua Lu; Michael J Rynkiewicz; Chiou-Ying Yang; Guillermo Madico; Hillary M Perkins; Marly I Roche; Barbara A Seaton; Jacqueline Sharon
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2014-08

Review 7.  The atypical lipopolysaccharide of Francisella.

Authors:  Nihal A Okan; Dennis L Kasper
Journal:  Carbohydr Res       Date:  2013-07-02       Impact factor: 2.104

8.  The binding sites of monoclonal antibodies to the non-reducing end of Francisella tularensis O-antigen accommodate mainly the terminal saccharide.

Authors:  Zhaohua Lu; Michael J Rynkiewicz; Chiou-Ying Yang; Guillermo Madico; Hillary M Perkins; Qi Wang; Catherine E Costello; Joseph Zaia; Barbara A Seaton; Jacqueline Sharon
Journal:  Immunology       Date:  2013-11       Impact factor: 7.397

9.  B-cell epitopes in GroEL of Francisella tularensis.

Authors:  Zhaohua Lu; Michael J Rynkiewicz; Guillermo Madico; Sheng Li; Chiou-Ying Yang; Hillary M Perkins; Seshi R Sompuram; Vani Kodela; Tong Liu; Timothy Morris; Daphne Wang; Marly I Roche; Barbara A Seaton; Jacqueline Sharon
Journal:  PLoS One       Date:  2014-06-26       Impact factor: 3.240

10.  Aerosol prime-boost vaccination provides strong protection in outbred rabbits against virulent type A Francisella tularensis.

Authors:  Katherine J O'Malley; Jennifer D Bowling; Elizabeth Stinson; Kelly S Cole; Barbara J Mann; Prachi Namjoshi; Karsten R O Hazlett; Eileen M Barry; Douglas S Reed
Journal:  PLoS One       Date:  2018-10-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.